Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine loaded with allogeneic DIPG tumor lysate
- Development stage
- Unknown
- Lead developer
- Fundació Sant Joan de Déu
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The autologous dendritic cell vaccine loaded with allogeneic DIPG tumor lysate is an investigational cellular immunotherapy developed by Fundació Sant Joan de Déu for the treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG). The vaccine is produced by harvesting a patient's monocytes via leukapheresis, maturing them into dendritic cells ex vivo, and pulsing them with a lysate derived from a pool of allogeneic, K27M-mutated DIPG tumor cell lines. This process allows the dendritic cells to present tumor-specific antigens to the patient's immune system. Administered intradermally, the vaccine is designed to induce a robust T-cell mediated immune response against the aggressive brainstem tumor. Clinical evaluation in a Phase Ib study (NCT02840123) demonstrated safety and the induction of specific immune responses in both peripheral blood and cerebrospinal fluid.
- Other names
- autologous dendritic cell vaccine pulsed with allogeneic DIPG tumor lysateDIPG-DC vaccine
02
Targets
Tumor-associated antigens derived from H3K27M-positive DIPG tumor lysate
Beyond the preview
Go deeper on autologous dendritic cell vaccine loaded with allogeneic DIPG tumor lysate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine loaded with allogeneic DIPG tumor lysate.